Guadecitabine | 929901-49-5

• 物质功能分类: 生物化工 - 生化试剂 - 激动剂抑制剂
• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷酸
• 英文名称: Guadecitabine
• 英文别名: [(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methyl [(2R,3S,5R)-5-(4-amino-2-oxo-1,3,5-triazin-1-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate
• CAS: 929901-49-5
• 化学式: C₁₈H₂₄N₉O₁₀P
• 分子量: 557.4
• InChiKey: GUWXKKAWLCENJA-WGWHJZDNSA-N

物化性质

• 沸点：
  956.4±75.0 °C(Predicted)
• 密度：
  2.24±0.1 g/cm3(Predicted)
• 溶解度：
  可溶于水

计算性质

• 辛醇/水分配系数(LogP)：
  -4.1
• 重原子数：
  38
• 可旋转键数：
  8
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  271
• 氢给体数：
  6
• 氢受体数：
  11

文献信息

• DNMT inhibitor as solid tumor therapeutic drug
  申请人：OHARA PHARMACEUTICAL CO., LTD.

  公开号：US11173174B2

  公开（公告）日：2021-11-16

  [Problem] To provide, in place of injected agents (such as Vidaza® and Dacogen®) clinically used as therapeutic drugs for high-risk myelodysplastic syndromes, a medicine as a therapeutic drug or a prophylactic drug for various advanced solid tumors, said medicine having high stability with respect to cytidine deaminase which is a hydrolytic metabolic enzyme, being absorbed into the body even by oral administration, and having an effect of being integrated into a nucleic acid biosynthetic route and inhibiting DNA methyltransferases, i.e., DNMTs. [Solution] The aforementioned problem is solved by a novel compound represented by formula (I). (In the formula, R is a hydroxyl group or a hydrogen atom, and R1 and R2 are each a benzyl group that may have a substituent.)

  问题 提供一种药物，代替临床上用作高危骨髓增生异常综合征治疗药物的注射剂（如 Vidaza® 和 Dacogen®），用作各种晚期实体瘤的治疗药物或预防药物、所述药物对胞苷脱氨酶（一种水解代谢酶）具有高度稳定性，即使口服也能被人体吸收，并具有融入核酸生物合成途径和抑制 DNA 甲基转移酶（即 DNA 甲基转移酶）的作用。e.,DNMTs。 [解决方案］ 由式（I）表示的新型化合物解决了上述问题。(式中，R 是羟基或氢原子，R1 和 R2 各为可带有取代基的苄基)。
• INDUCTION OF SYNTHETIC LETHALITY WITH EPIGENETIC THERAPY
  申请人：The Johns Hopkins University

  公开号：EP3635396A1

  公开（公告）日：2020-04-15
• NOVEL DNMT INHIBITOR AS SOLID TUMOR THERAPEUTIC DRUG
  申请人：OHARA PHARMACEUTICAL CO., LTD.

  公开号：US20200061093A1

  公开（公告）日：2020-02-27

  [Problem] To provide, in place of injected agents (such as Vidaza® and Dacogen®) clinically used as therapeutic drugs for high-risk myelodysplastic syndromes, a medicine as a therapeutic drug or a prophylactic drug for various advanced solid tumors, said medicine having high stability with respect to cytidine deaminase which is a hydrolytic metabolic enzyme, being absorbed into the body even by oral administration, and having an effect of being integrated into a nucleic acid biosynthetic route and inhibiting DNA methyltransferases, i.e., DNMTs. [Solution] The aforementioned problem is solved by a novel compound represented by formula (I). (In the formula, R is a hydroxyl group or a hydrogen atom, and R 1 and R 2 are each a benzyl group that may have a substituent.)
• COMBINATION OF ISOINDOLINONE DERIVATIVES WITH SGI-110
  申请人：ASTEX THERAPEUTICS LIMITED

  公开号：US20200207711A1

  公开（公告）日：2020-07-02

  The invention provides a combination comprising: (i) a compound of formula (I o ): or a tautomer or a solvate or a pharmaceutically acceptable salt thereof, wherein the various substituents are as defined in the claims; and (ii) a compound which is SGI-110 or a tautomer or a solvate or a pharmaceutically acceptable salt thereof. Also provided are pharmaceutical compositions containing the combinations and medical uses of the combinations.
• IMPROVED PROCESSES FOR THE PREPARATION OF GUADECITABINE AND INTERMEDIATES THEREOF
  申请人：TEVA CZECH INDUSTRIES s.r.o.

  公开号：US20210147466A1

  公开（公告）日：2021-05-20

  Described are procedures and intermediates for the preparation of guadecitabine, and guadecitabine salts and solid state forms thereof.